R., Hema published the artcileRole of coformers in solubility enhancement of poorly soluble drugs through cocrystallization: an overview, Recommanded Product: 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, the main research area is review coformer solubility soluble drug cocrystn.
Improving the solubility of poorly soluble pharmaceuticals is a key problem in the pharmaceutical industry, and it can be solved using a range of methods, such as particle size reduction, surface modification, and other procedures. Cocrystn. is a new method for enhancing solubility in the pharmaceutical industry, which can be done with the help of cocrystal former (Coformer). These are watersol. stoichiometric cocrystals of the active pharmaceutical ingredient (API) with water-soluble small mol. coformers such as ascorbic acid, Nicotinamide, etc. Selection of coformer is a principal challenge in evolution of cocrystals, which can be done by various approaches such as trial and error, supra mol. synthon, virtual screening, etc. Hydrogen bonding, halogen bonding, and π -π interactions all play a part in the development of cocrystals. Moisture absorption, cocrystal reactant dissolution, cocrystal nucleation, and growth are all factors that impact crystal formation. Cocrystals can be prepared by various methods such as Solution evaporation method, Solution cooling crystallization, Solid state grinding, Liquid assisted grinding method, Hot melt extrusion, etc. This review complies the various research works on cocrystals.
International Journal of Pharmaceutical Sciences Review and Research published new progress about Chemical stability. 72509-76-3 belongs to class pyridine-derivatives, name is 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, and the molecular formula is C18H19Cl2NO4, Recommanded Product: 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate.